A VA study on the relationship between GLP-1 weight-loss drugs and 175 diseases and conditions supports a lot of what scientists already suspected about potential benefits, but contains a few surprises, too. The findings, published Monday in the journal Nature Medicine and based on an analysis of medical records from about 2.5 million patients in the VA system, support the idea that the medications might be able to help patients with Alzheimer’s disease and who are suffering from substance abuse involving alcohol, cannabis and narcotics.
